Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,980,000 shares, a growth of 5.3% from the March 15th total of 3,780,000 shares. Currently, 4.6% of the company's shares are short sold. Based on an average trading volume of 968,700 shares, the days-to-cover ratio is presently 4.1 days.

Humacyte Stock Up 6.6 %

Shares of NASDAQ HUMA traded up $0.19 during midday trading on Tuesday, reaching $3.06. 1,427,237 shares of the company's stock were exchanged, compared to its average volume of 971,874. Humacyte has a 52-week low of $1.96 and a 52-week high of $5.60. The stock has a market capitalization of $364.38 million, a PE ratio of -2.85 and a beta of 1.46. The company has a debt-to-equity ratio of 1.20, a quick ratio of 4.52 and a current ratio of 4.52. The business's fifty day moving average price is $3.53 and its two-hundred day moving average price is $2.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same period last year, the firm posted ($0.21) EPS. Analysts forecast that Humacyte will post -0.9 EPS for the current year.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its stake in Humacyte by 261.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company's stock valued at $26,000 after buying an additional 6,504 shares in the last quarter. American International Group Inc. acquired a new stake in Humacyte during the second quarter valued at approximately $27,000. Whittier Trust Co. of Nevada Inc. acquired a new stake in Humacyte during the fourth quarter valued at approximately $28,000. Victory Capital Management Inc. acquired a new stake in shares of Humacyte during the 4th quarter worth approximately $29,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Humacyte during the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 price objective on shares of Humacyte in a research report on Monday, April 1st. Benchmark reissued a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research report on Monday, March 25th. Finally, Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective on shares of Humacyte in a research report on Tuesday, March 26th.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).